Your browser doesn't support javascript.
loading
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
Xu, Binghe; Ma, Fei; Wang, Tao; Wang, Shusen; Tong, Zhongsheng; Li, Wei; Wu, Xinhong; Wang, Xiaojia; Sun, Tao; Pan, Yueyin; Yao, Herui; Wang, Xian; Luo, Ting; Yang, Jin; Zeng, Xiaohua; Zhao, Weihong; Cong, Xiuyu Julie; Chen, Jiongjie.
Afiliación
  • Xu B; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Ma F; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang T; Department of Breast Cancer, The Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Wang S; Department of Medical Oncology, Sun Yet-Sen University Cancer Center, Guangzhou, China.
  • Tong Z; Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Li W; Department of Medical Oncology, The First Hospital of Jilin University, Changchun, China.
  • Wu X; Department of Breast Oncology, Hubei Cancer Hospital, Wuhan, China.
  • Wang X; Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Sun T; Department of Medical Oncology, Liaoning Cancer Hospital &Institute, Shenyang, China.
  • Pan Y; Department of Medical Oncology, Anhui Provincial Hospital, Hefei, China.
  • Yao H; Department of Medical Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Wang X; Department of Medical Oncology, Sir Run Run Shaw Hospital, Hangzhou, China.
  • Luo T; Department of Head, Neck and Mammary Gland Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Yang J; Department of Medical Oncology, First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Zeng X; Department of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
  • Zhao W; Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China.
  • Cong XJ; Everest Medicines, Shanghai, China.
  • Chen J; Everest Medicines, Shanghai, China.
Int J Cancer ; 152(10): 2134-2144, 2023 05 15.
Article en En | MEDLINE | ID: mdl-36621000
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoconjugados / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials Límite: Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoconjugados / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials Límite: Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: China